Lung Cancer | Specialty

Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

July 16th 2024

Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.

Examining the use of PD-L1 and tTMB in the CASPIAN Trial

July 16th 2024

Key opinion leaders examine the PD-L1 expression and tissue tumor mutational burden (TMB) data from the CASPIAN trial, which evaluated the combination of durvalumab with platinum-etoposide for extensive-stage small cell lung cancer (ES-SCLC), weighing the potential predictive value of PD-L1 and tissue TMB in assessing progression-free survival (PFS) and objective response rate (ORR) outcomes.

MARIPOSA Study Insights

July 16th 2024

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

July 16th 2024

The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.

Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC

July 12th 2024

Health Canada has approved osimertinib/chemotherapy for advanced non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

July 12th 2024

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

Best Practices in Treating Early-Stage NSCLC

July 11th 2024

Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

July 9th 2024

Medical experts specializing in small cell lung cancer (SCLC) delve into the complex topic of immunotherapy resistance, exploring potential mechanisms, clinical implications, and potential strategies to overcome this challenge in the treatment of patients with SCLC.

Predictors of Immunotherapy Response in Limited and Extensive SCLC

July 9th 2024

Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

July 8th 2024

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

Navigating Between ADCs in NSCLC

July 8th 2024

The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.

European Commission Approves Osimertinib Plus Chemo for Advanced EGFR+ NSCLC

July 8th 2024

Frontline osimertinib plus chemotherapy has been approved in the European Union for adult patients with advanced EGFR-mutated non–small cell lung cancer.

Tiragolumab Plus Atezolizumab/Chemo Misses Survival End Points in Metastatic Nonsquamous NSCLC

July 8th 2024

First-line tiragolumab plus atezolizumab and chemotherapy failed to improve survival in advanced nonsquamous non–small cell lung cancer.

Examining 3-Year Update Data from the CASPIAN Trial

July 2nd 2024

A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.

cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

July 2nd 2024

Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.

Dr Punekar on the Evaluation of NT-112 in KRAS G12D+ Advanced Solid Tumors

July 2nd 2024

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

July 2nd 2024

Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.

Exploring the TROPION-Lung04 Study

July 2nd 2024

Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC

June 28th 2024

Taofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.